Synthetic Library: High-throughput continuous mutation of large molecules’ amino acids Diversity: Large molecules with differences in structure, size, amino acid composition and arrangement Size: The number of all large molecules in the large molecule libraryMore
ABLINK's independently developed monoclonal antibody screening platform overcomes the difficulties of phage display library technology and high throughput screening technology, breaking through the technical barriers of human monoclonal antibodies, peptides protein drugs, and TCR drugs discovery. We can provide a camel immunized "mini" library with a size greater than 10^9 within two weeks, encoded correctly and unique sequence >90%. We can also provide a fully synthetic "mini" antibody library with a size greater than 10^10 within 4-6 weeks, with an efficiency of 1-3 CDR region mutations greater than 90%. In addition, we can construct libraries based on different immune sources such as humans, alpacas, camels, sharks, mice, and rabbits, and use ‘library technology’ for humanization, affinity maturation, bispecific antibody modification, etc. to meet the needs of different customers.More
Ablink's self-developed chemokine receptor-optimized next-generation BCMA CAR-T has entered Phase 1 of scientific research and clinical trials. It has the ability to enhance tumor targeting and can effectively eliminate tumors by using only 1/10 of the conventional CAR-T cell dose tumor.More
Ablink takes the industry's advanced AI tools as a starting point, uses the company's own large amount of experimental data for reliability verification and iteration, and integrates and forms a "specialized and refined" localized functional platform for the real pain points in the research and development of macromolecular drugs. The platform is organically integrated in multiple steps of antibody drug discovery, including antibody drug discovery, antibody engineering, antibody humanization, antibody/enzyme immunogenicity removal, antibody/protein affinity maturation, antibody developability assessment and Stability optimization and design of innovative antibody formats provide customers with integrated drug discovery services for preclinical candidate antibodies based on targets.More
